- Home
- NRT vs IGC Comparison
NRT vs IGC Comparison
Compare NRT & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRT
- IGC
- Stock Information
- Founded
- NRT 1975
- IGC 2005
- Country
- NRT United States
- IGC United States
- Employees
- NRT N/A
- IGC N/A
- Industry
- NRT Oil & Gas Production
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- NRT Energy
- IGC Health Care
- Exchange
- NRT Nasdaq
- IGC Nasdaq
- Market Cap
- NRT 46.4M
- IGC 20.2M
- IPO Year
- NRT N/A
- IGC N/A
- Fundamental
- Price
- NRT $4.91
- IGC $0.36
- Analyst Decision
- NRT
- IGC Strong Buy
- Analyst Count
- NRT 0
- IGC 2
- Target Price
- NRT N/A
- IGC $3.88
- AVG Volume (30 Days)
- NRT 18.0K
- IGC 7.2M
- Earning Date
- NRT 08-29-2025
- IGC 08-07-2025
- Dividend Yield
- NRT 9.78%
- IGC N/A
- EPS Growth
- NRT 24.05
- IGC N/A
- EPS
- NRT 0.59
- IGC N/A
- Revenue
- NRT $6,184,173.00
- IGC $1,271,000.00
- Revenue This Year
- NRT N/A
- IGC $15.26
- Revenue Next Year
- NRT N/A
- IGC $3.41
- P/E Ratio
- NRT $8.46
- IGC N/A
- Revenue Growth
- NRT 18.55
- IGC N/A
- 52 Week Low
- NRT $3.88
- IGC $0.25
- 52 Week High
- NRT $6.77
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- NRT 45.60
- IGC 55.26
- Support Level
- NRT $4.65
- IGC $0.30
- Resistance Level
- NRT $5.03
- IGC $0.36
- Average True Range (ATR)
- NRT 0.19
- IGC 0.03
- MACD
- NRT -0.02
- IGC 0.00
- Stochastic Oscillator
- NRT 42.82
- IGC 31.06
About NRT North European Oil Royality Trust
North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.